發(fā)布時(shí)間：2018-03-09 22:05

  本文選題：易普利姆瑪　切入點(diǎn)：晚期黑色素瘤　出處：《重慶醫(yī)科大學(xué)》2017年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：目的:對(duì)易普利姆瑪治療黑色素瘤患者的有效性及安全性進(jìn)行meta分析。方法:計(jì)算機(jī)檢索Pub Med,the Cochrane Library,Embase,中國(guó)知網(wǎng)、萬(wàn)方和維普數(shù)據(jù)庫(kù)。依據(jù)設(shè)定的納入及排除標(biāo)準(zhǔn)選取論文,并且提取信息、評(píng)估研究質(zhì)量后,運(yùn)用Rev Man 5.3軟件對(duì)符合要求的研究進(jìn)行meta分析。結(jié)果:經(jīng)篩選后有4篇論文滿(mǎn)足要求,納入的病例總數(shù)是2622例。Meta分析結(jié)果顯示:與對(duì)照組相比,易普利姆瑪組1年無(wú)進(jìn)展生存率(RR=0.94,95%CI:0.91~0.98,P=0.001)、1年總生存率(RR=0.79,95%CI:0.72~0.87,P0.00001)較高,具有統(tǒng)計(jì)學(xué)差異。2年無(wú)進(jìn)展生存率(RR=0.99,95%CI:0.97~1.01,P=0.45)及3年總生存率(RR=0.93,95%CI:0.84~1.03,P=0.17)均無(wú)統(tǒng)計(jì)學(xué)差異。易普利姆瑪組患者皮疹(RR=2.43,95%CI:1.64~3.61,P0.00001)、瘙癢(RR=2.35,95%CI:1.67~3.29,P0.00001)、腹瀉(RR=1.82,95%CI:1.47~2.25,P0.00001)、結(jié)腸炎(RR=11.21,95%CI:6.20~20.30,P0.00001)、丙氨酸氨基轉(zhuǎn)移酶增高(RR=3.57,95%CI:1.92~6.62,P0.0001)、天門(mén)冬氨酸氨基轉(zhuǎn)移酶增高(RR=3.81,95%CI:2.85~5.09,P0.00001)的發(fā)生率均較高。結(jié)論:易普利姆瑪可提高患者1年無(wú)進(jìn)展生存率、1年總生存率,但在2年無(wú)進(jìn)展生存率及3年總生存率方面未顯示出優(yōu)勢(shì),且易普利姆瑪增加了患者出現(xiàn)皮疹、瘙癢、腹瀉、結(jié)腸炎和轉(zhuǎn)氨酶升高的風(fēng)險(xiǎn)。
[Abstract]:Objective: to analyze the efficacy and safety of Eprimma in the treatment of melanoma by meta. Methods: the Pub Medsite, the Cochrane Library Embase, the Wan-Fang and Weip databases were searched by computer, and the papers were selected according to the established inclusion and exclusion criteria. After extracting the information and evaluating the quality of the research, meta analysis was carried out by using Rev Man 5.3 software. Results: after screening, 4 papers met the requirements. The total number of cases included was 2622. Meta-analysis showed that compared with the control group, the 1-year progression-free survival rate of the Eprimma group was higher than that of the control group, and the 1 year overall survival rate was higher than that of the control group. There was no statistical difference in the 2-year progression-free survival rate (RRN 0.99 ~ 95CI0.97 P0.45) and the 3-year overall survival rate (RRN 0.9395CI0.84N 1.03P0.17). There was no statistical difference in the 2-year progressive survival rate (RR2.4395CI1.643.61C), RRR2.3595CI1.673.29P0.00001N) and the overall 3-year survival rate (RRR1.0395CI0.841.0395CI0.80.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395CI0.8395C0.17), RR2.395CI1.643.61C (P 0.00001), RRR1.82CI1.82CI1.82CI1.25P0.00001a, RR11.21a, CI6.2020.30P0011a, the elevation of the alanine aminotransferase R53.951a in R53.959CI1.000. The incidence of RRX 3.81C 95% CI: 2.85% 5.09% P0.00001) was higher. Conclusion: the 1-year progression-free survival rate and 1-year overall survival rate can be improved by Iprimma. But there was no advantage in 2-year progression-free survival and 3-year overall survival, and Eprimma increased the risk of rash, pruritus, diarrhea, colitis and elevated transaminase.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R739.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 毛麗麗;于思帆;陳含笑;白雪;王軒;盛錫楠;崔傳亮;遲志宏;唐碧霞;連斌;鄢謝橋;李思明;郭軍;斯璐;;伊馬替尼治療78例KIT變異的晚期黑色素瘤的療效和安全性[J];中國(guó)腫瘤生物治療雜志;2017年03期

2 田紅;肖桂芝;田苗;劉永貴;賀星;陳常青;;黑色素瘤治療藥物的研究進(jìn)展[J];現(xiàn)代藥物與臨床;2015年07期

3 俎明;孔燕;斯璐;梁龍;代杰;李強(qiáng);張虔男;郭軍;;ERBB4基因突變與ERBB4蛋白表達(dá)在黏膜和肢端黑色素瘤中的臨床意義[J];臨床腫瘤學(xué)雜志;2012年05期

4 ;中國(guó)黑色素瘤診治指南(2011版)[J];臨床腫瘤學(xué)雜志;2012年02期

，

本文編號(hào)：1590453